{"disease":{"id":"diabetes-type-2","name":"diabetes type 2"},"drugs":{"marketed":[{"drug_id":"semaglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ozempic","generic_name":"semaglutide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":90,"revenue":"27400","mechanism":"Semaglutide, a GLP-1 analogue, lowers blood glucose by stimulating insulin and inhibiting glucagon secretion in a glucose-dependent manner, and delays gastric emptying."},{"drug_id":"tirzepatide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mounjaro","generic_name":"TIRZEPATIDE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"GIP receptor and GLP-1 receptor","drug_class":"Dual GIP/GLP-1 receptor agonist","quality_score":84,"revenue":"15530","mechanism":"Tirzepatide is a dual GIP and GLP-1 receptor agonist with C20 fatty diacid for albumin binding."},{"drug_id":"dulaglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trulicity","generic_name":"DULAGLUTIDE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":63,"revenue":"7200","mechanism":"Dulaglutide activates GLP-1 receptors, increasing insulin release and decreasing glucagon secretion and gastric emptying."},{"drug_id":"empagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jardiance","generic_name":"empagliflozin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":66,"revenue":"6500","mechanism":"SYNJARDY combines empagliflozin, which inhibits SGLT2 to increase urinary glucose excretion, and metformin HCl, which improves glucose tolerance and insulin sensitivity."},{"drug_id":"dapagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Farxiga","generic_name":"DAPAGLIFLOZIN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":69,"revenue":"6300","mechanism":"Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine."},{"drug_id":"insulin-glargine","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lantus","generic_name":"INSULIN GLARGINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":70,"revenue":"4800","mechanism":"Lantus works by mimicking the action of natural insulin to lower blood sugar levels."},{"drug_id":"sitagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Januvia","generic_name":"SITAGLIPTIN","company_name":"Zydus Lifesciences","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":75,"revenue":"3200","mechanism":"Januvia works by blocking an enzyme that breaks down hormones that help the body release insulin."},{"drug_id":"liraglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Victoza","generic_name":"liraglutide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":35,"revenue":"3200","mechanism":null},{"drug_id":"insulin-lispro","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humalog","generic_name":"INSULIN LISPRO","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin Analog [EPC]","quality_score":70,"revenue":"2200","mechanism":"Humalog works by mimicking the natural hormone insulin to help cells absorb glucose from the bloodstream."},{"drug_id":"canagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invokana","generic_name":"CANAGLIFLOZIN","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor","quality_score":71,"revenue":"800","mechanism":"Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption."},{"drug_id":"bi-1356","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tradjenta","generic_name":"BI 1356","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":71,"revenue":"800","mechanism":"Tradjenta works by blocking the DPP-4 enzyme, which normally breaks down incretin hormones that help regulate blood sugar levels."},{"drug_id":"linagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tradjenta","generic_name":"LINAGLIPTIN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":75,"revenue":"800","mechanism":"Tradjenta works by blocking an enzyme that breaks down hormones that help the body release insulin."},{"drug_id":"vildagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jalra","generic_name":"VILDAGLIPTIN","company_name":"","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"vildagliptin","quality_score":37,"revenue":"159","mechanism":""},{"drug_id":"acetohexamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dymelor","generic_name":"ACETOHEXAMIDE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"acetohexamide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"bexagliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brenzavvy","generic_name":"BEXAGLIFLOZIN","company_name":"Theracosbio","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":58,"revenue":null,"mechanism":"Bexagliflozin inhibits SGLT2 to reduce renal glucose reabsorption and increase urinary glucose excretion."},{"drug_id":"metformin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucophage","generic_name":"metformin","company_name":"Generic (originally Merck Serono/Lipha)","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Activates AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity without causing hypoglycemia."},{"drug_id":"ertugliflozin-15-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 15 mg","generic_name":"ertugliflozin-15-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"januvia","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Januvia","company_name":"Johns Hopkins University","drug_phase":"discontinued","molecular_target":"Dipeptidyl peptidase 2, Dipeptidyl peptidase 8, Dipeptidyl peptidase 9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"duvie","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"duvie","company_name":"Pusan National University Hospital","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor alpha, Peroxisome proliferator-activated receptor gamma","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"liraglutid","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Liraglutid","company_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"pioglitazone","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Actos","generic_name":"pioglitazone","company_name":"Takeda","drug_phase":"marketed","molecular_target":"CDGSH iron-sulfur domain-containing protein 2, Bile salt export pump, CDGSH iron-sulfur domain-containing protein 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"saxenda","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Saxenda","company_name":"Seoul National University Hospital","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"victoza","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Victoza","company_name":"Hanmi Pharmaceutical Company Limited","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"glucophage","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glucophage","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"glipizide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucotrol","generic_name":"GLIPIZIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea [EPC]","quality_score":62,"revenue":null,"mechanism":"Glucotrol works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells."},{"drug_id":"lantus","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lantus","company_name":"Rijnstate Hospital","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"mitiglinide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MITIGLINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"mitiglinide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tofogliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apleway","generic_name":"TOFOGLIFLOZIN","company_name":"","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"gliclazide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diabyl","generic_name":"GLICLAZIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"gliclazide","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"lobeglitazone","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duvie","generic_name":"LOBEGLITAZONE","company_name":"Chong Kun Dang","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor gamma","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"lyumjev","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lyumjev","company_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"dapa","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DAPA","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"nateglinide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Starlix","generic_name":"NATEGLINIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Glinide [EPC]","quality_score":75,"revenue":null,"mechanism":"Starlix works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells."},{"drug_id":"glymidine","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gondafon","generic_name":"GLYMIDINE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"glymidine","quality_score":null,"revenue":null,"mechanism":"Gondafon works by stimulating insulin release from the pancreas."},{"drug_id":"voglibose","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glustat","generic_name":"VOGLIBOSE","company_name":"","drug_phase":"marketed","molecular_target":"Lysosomal alpha-glucosidase","drug_class":"voglibose","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"alogliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nesina","generic_name":"ALOGLIPTIN","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"Dipeptidyl Peptidase 4 Inhibitor","quality_score":65,"revenue":null,"mechanism":"Nesina works by blocking an enzyme that breaks down incretin hormones, allowing more insulin to be released and less glucagon."},{"drug_id":"insulin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humulin","generic_name":"insulin","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Lck","drug_class":"Insulin Analog [EPC]","quality_score":60,"revenue":null,"mechanism":"Humulin works by binding to insulin receptors on cells, triggering a cascade of signals that lower blood glucose levels."},{"drug_id":"ertugliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Steglatro","generic_name":"ERTUGLIFLOZIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter","drug_class":"","quality_score":54,"revenue":null,"mechanism":"Steglatro works by blocking the kidneys' ability to reabsorb glucose, allowing excess glucose to be excreted in the urine."},{"drug_id":"lixisenatide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adlyxin","generic_name":"LIXISENATIDE","company_name":"Sanofi-Aventis Us Llc","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"Insulin Analog [EPC]","quality_score":10,"revenue":null,"mechanism":"Adlyxin works by mimicking the action of the GLP-1 hormone to help regulate blood sugar levels."},{"drug_id":"ertugliflozin-5-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 5 mg","generic_name":"ertugliflozin-5-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"sotagliflozin","indication_name":"Diabetes mellitus type 2 at increased risk of cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inpefa","generic_name":"SOTAGLIFLOZIN","company_name":"Lexicon Pharms Inc","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"Sodium-Glucose Cotransporter 2 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Inpefa works by blocking the sodium/glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood sugar levels."},{"drug_id":"buformin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butformin","generic_name":"BUFORMIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"buformin","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"troglitazone","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezulin","generic_name":"TROGLITAZONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Forkhead box protein M1","drug_class":"troglitazone","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tolbutamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aglicid","generic_name":"TOLBUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"albiglutide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Albugon","generic_name":"ALBIGLUTIDE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"miglitol","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glyset","generic_name":"MIGLITOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Lysosomal alpha-glucosidase","drug_class":"alpha-Glucosidase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Glyset works by delaying the breakdown of carbohydrates in the gut, allowing less glucose to enter the bloodstream."},{"drug_id":"forxiga","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Forxiga","company_name":"AstraZeneca Turkey","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"jardiance","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Jardiance","company_name":"University of Louisville","drug_phase":"marketed","molecular_target":"Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1, Sodium/glucose cotransporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"farxiga","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Farxiga","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"rybelsus","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rybelsus","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"humalog","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humalog","company_name":"Halozyme Therapeutics","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gemigliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zemiglo","generic_name":"GEMIGLIPTIN","company_name":"","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"gemigliptin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mounjaro","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mounjaro","company_name":"Nicholas Skertich","drug_phase":"marketed","molecular_target":"Gastric inhibitory polypeptide receptor, Glucagon-like peptide 1 receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"anagliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suiny","generic_name":"ANAGLIPTIN","company_name":"","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"ipragliflozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suglat","generic_name":"IPRAGLIFLOZIN","company_name":"","drug_phase":"marketed","molecular_target":"Sodium/glucose cotransporter 2","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"glisoxepide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glisepin","generic_name":"GLISOXEPIDE","company_name":"","drug_phase":"phase_2","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"glisoxepide","quality_score":28,"revenue":null,"mechanism":"Glisoxepide works by blocking potassium channels in the pancreas, allowing more insulin to be released."},{"drug_id":"dapaglifozin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dapaglifozin","company_name":"MedImmune LLC","drug_phase":"phase_3","molecular_target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"evogliptin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suganon","generic_name":"EVOGLIPTIN","company_name":"Dong-A ST","drug_phase":"marketed","molecular_target":"Dipeptidyl peptidase 4","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"glibenclamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micronase","generic_name":"glibenclamide","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"imeglimin","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Twymeeg","generic_name":"IMEGLIMIN","company_name":"SUMITOMO DAINIPPON PHARMA Co., Ltd.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"tradjenta","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tradjenta","company_name":"EMS","drug_phase":"discontinued","molecular_target":"Dipeptidyl peptidase 9, Prolyl endopeptidase FAP, Dipeptidyl peptidase 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"glimepiride","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amaryl","generic_name":"GLIMEPIRIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea [EPC]","quality_score":62,"revenue":null,"mechanism":"Amaryl works by binding to the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel, closing the channel and depolarizing the pancreatic beta cell membrane, leading to insulin release."},{"drug_id":"acarbose","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Precose","generic_name":"ACARBOSE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Sucrase-isomaltase, intestinal","drug_class":"alpha-Glucosidase Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"chlorpropamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diabinese","generic_name":"CHLORPROPAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"carbutamide","indication_name":"Diabetes mellitus type 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Burcol","generic_name":"CARBUTAMIDE","company_name":"","drug_phase":"phase_2","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"carbutamide","quality_score":null,"revenue":null,"mechanism":"Burcol works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells."}],"pipeline":[],"offLabel":[],"totalMarketed":65,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02958995","title":"Epidemiologic Study Of Diabetes And Cancer Risk","phase":"","overall_status":"COMPLETED","enrollment_count":2738161,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04017221","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":1249636,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT06563401","title":"Mortality and Cardiovascular Diseases in Adult-onset Type 1 Diabetes","phase":"","overall_status":"RECRUITING","enrollment_count":900000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03492580","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":714582,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04572165","title":"Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data","phase":"","overall_status":"UNKNOWN","enrollment_count":600000,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05161429","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","phase":"","overall_status":"UNKNOWN","enrollment_count":550000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05882071","title":"Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":547150,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05730582","title":"Increasing Uptake of EHR-enabled Population Health Outreach Strategies to Improve Diabetes Screening","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500000,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT05162014","title":"To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin","phase":"","overall_status":"COMPLETED","enrollment_count":494679,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03464045","title":"Empa PASS on Urinary Tract Malignancies","phase":"","overall_status":"COMPLETED","enrollment_count":344995,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02864914","title":"Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":333580,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03817463","title":"A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":327624,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06330480","title":"Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":320000,"lead_sponsor_name":"Prof. Dr. Folkert W. Asselbergs","has_results":false},{"nct_id":"NCT02958956","title":"Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.","phase":"","overall_status":"COMPLETED","enrollment_count":236507,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03363464","title":"Comparative Effectiveness of Empagliflozin in the US","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230000,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT07513259","title":"Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":203424,"lead_sponsor_name":"Chung Shan Medical University","has_results":false},{"nct_id":"NCT02636192","title":"Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02197078","title":"Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin","phase":"","overall_status":"COMPLETED","enrollment_count":189426,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03092752","title":"Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV","phase":"","overall_status":"COMPLETED","enrollment_count":162116,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06659744","title":"Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims","phase":"","overall_status":"COMPLETED","enrollment_count":158310,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT02857764","title":"Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":127690,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06251323","title":"Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)","phase":"NA","overall_status":"RECRUITING","enrollment_count":119680,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT02993614","title":"Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors","phase":"","overall_status":"COMPLETED","enrollment_count":99999,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05465317","title":"Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease","phase":"","overall_status":"COMPLETED","enrollment_count":62197,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06914102","title":"Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":58387,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT00659282","title":"Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":57610,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03534921","title":"Improving Diabetes Outcomes for People With Severe Mental Illness (SMI)","phase":"","overall_status":"COMPLETED","enrollment_count":46564,"lead_sponsor_name":"University of York","has_results":false},{"nct_id":"NCT06659718","title":"Emulation of the SOUL Diabetes Trial in Healthcare Claims","phase":"","overall_status":"COMPLETED","enrollment_count":43650,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT06351748","title":"Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)","phase":"","overall_status":"COMPLETED","enrollment_count":34238,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06552923","title":"Extension for Community Health Outcomes (ECHO) Diabetes Program","phase":"NA","overall_status":"COMPLETED","enrollment_count":32796,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT01696266","title":"An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":29304,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06914141","title":"Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction","phase":"","overall_status":"COMPLETED","enrollment_count":28118,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03993132","title":"A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":26774,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06659679","title":"Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims","phase":"","overall_status":"COMPLETED","enrollment_count":26126,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04928248","title":"Design, Implementation and Evaluation of Scalable Decision Support for Diabetes Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":25915,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT03249506","title":"Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)","phase":"","overall_status":"COMPLETED","enrollment_count":25358,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04295005","title":"A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists","phase":"","overall_status":"COMPLETED","enrollment_count":24500,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05441267","title":"A Study of Cardiovascular Events iN Diabetes Plus","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT03627039","title":"Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05874635","title":"Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Signos Inc","has_results":false},{"nct_id":"NCT04034524","title":"Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT01991795","title":"A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":19271,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02587936","title":"Improving Chronic Disease Management With Pieces","phase":"NA","overall_status":"COMPLETED","enrollment_count":18268,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":true},{"nct_id":"NCT06573905","title":"Mapping Diabetes in Quebec: Validating Medico-administrative Algorithms for Type 1 Diabetes, Type 2 Diabetes and LADA","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":17271,"lead_sponsor_name":"Universite du Quebec en Outaouais","has_results":false},{"nct_id":"NCT06642272","title":"A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":17200,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT05239572","title":"Scaling Up NCD Interventions in South East Asia","phase":"NA","overall_status":"COMPLETED","enrollment_count":16850,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT04937816","title":"This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations","phase":"","overall_status":"COMPLETED","enrollment_count":16746,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05782881","title":"High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program","phase":"NA","overall_status":"UNKNOWN","enrollment_count":16000,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}